Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Intracerebral Hemorrhage Outcome Doesn’t Differ by Anticoagulant

By David Douglas (Reuters Health) | on May 16, 2017 | 0 Comment
Latest News
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Mortality and functional outcomes in patients with anticoagulant-related intracerebral hemorrhage (ICH) do not appear to be associated with the type of oral anticoagulants used, according to an international group of researchers.

You Might Also Like
  • Worse Intracerebral Hemorrhage with Low Serum Calcium
  • Low Risk of Brain Hemorrhage in Ground-Level Fall with Antiplatelets, Anticoagulants
  • Platelets and Antiplatelet Therapy in Patients with Nontraumatic Intracerebral Hemorrhage

In patients with atrial fibrillation, use of vitamin K antagonist (VKA) oral anticoagulants is associated with twice the incidence of ICH seen with non-vitamin K oral antagonists (NOACS), Dr. David J. Werring of University College London and colleagues note in Neurology. Both types of agents are similarly efficacious in preventing ischemic stroke, they add.

However, although several strategies have been developed for VKA reversal, this is not the case for NOACs. Thus NOAC-associated ICH might be larger, with a higher risk of hematoma expansion and worse outcome, the researchers hypothesized.

To investigate, they conducted an international pooled analysis involving 500 patients who had ICH while on oral anticoagulation. Patients with a secondary cause for ICH, such as major head trauma or vascular malformations, were excluded. In total 97 patients received NOACs and 403 got VKAs. Overall, 161 patients had died by 90 days, giving a crude mortality rate of 32 percent. There was no difference for all-cause 90-day mortality between the NOAC group (33 percent) and the VKA patients (31 percent). There also was no between-group difference in 30-day or 60-day mortality. The same was true of the rate of hematoma expansion (40 percent vs. 34 percent, P=0.45).

Good functional outcome defined as a discharge modified Rankin Scale score of 2 or less also did not differ significantly between groups. Although in univariable analysis the VKA group appeared to be more likely to be functionally independent at discharge (23 percent vs. 10 percent, P<0.001) this was not the case after adjustment and multivariable analysis. However, the researchers caution, "We do not know how widely NOAC adoption was within each source population, which could lead to confounding by indication." While recommending further study, they note that the findings do not support previous concerns about NOACs. "These results, together with previous observational and trial data, should help to reassure clinicians that NOAC-ICH does not seem to have worse outcome than VKA-ICH, despite the current limited access to specific NOAC reversal agents," Dr. Werring told Reuters Health by email. Dr. Christian T. Ruff, a specialist in cardiovascular medicine at Brigham and Women's Hospital in Boston, said, "This research highlights that sobering reality that anticoagulation-associated intracranial hemorrhages are devastating, regardless of agent. The main advantage of NOACs compared with warfarin and other vitamin K antagonists is that they cause half as many intracranial hemorrhages, even without a specific reversal agent."

Pages: 1 2 | Single Page

Topics: AnticoagulantanticoagulationED Critical CareIntercerebral HemmorrhageMortalityNeurologyOutcomePatient CareResearchRiskStrokeTreatment

Related

  • ACEP Clinical Policy on Thrombolytics for Management of Acute Ischemic Stroke

    July 3, 2025 - 0 Comment
  • Reflecting on Four Decades at ACEP’s Council

    June 28, 2025 - 0 Comment
  • Case Report: When Syncope Gets Hairy

    June 17, 2025 - 0 Comment

Current Issue

ACEP Now: July 2025

Download PDF

Read More

No Responses to “Intracerebral Hemorrhage Outcome Doesn’t Differ by Anticoagulant”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*


Current Issue

ACEP Now: July 2025

Download PDF

Read More

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603